J&J’s Tecvayli/Darzalex nod is the second under a new priority voucher scheme.
ApexOnco Front Page
Recent articles
Rinzimetostat efficacy wanes further as the company moves into phase 3.
The company hands its PD-L1 x VEGF bispecific back to ImmuneOnco.
Seven oncology approvals included nods for subcutaneous Rybrevant and Lunsumio.
Mocertatug rezetecan is starting its first western pivotal trials.
PersonGen’s LV009 takes the industry tally of clinical-stage projects to 14.
The holiday period included Genmab’s discontinuation of acasunlimab.
A deal with Jacobio is worth $100m up front.
